These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21718326)

  • 1. PET/CT in diagnosis of dementia.
    Berti V; Pupi A; Mosconi L
    Ann N Y Acad Sci; 2011 Jun; 1228():81-92. PubMed ID: 21718326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dementia spectrum disorders: lessons learnt from decades with PET research.
    Wilson H; Pagano G; Politis M
    J Neural Transm (Vienna); 2019 Mar; 126(3):233-251. PubMed ID: 30762136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography imaging in dementia.
    Herholz K; Carter SF; Jones M
    Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography in dementia.
    Santens P; Petit H
    Acta Neurol Belg; 1997 Sep; 97(3):192-5. PubMed ID: 9345592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia.
    Eisenmenger LB; Huo EJ; Hoffman JM; Minoshima S; Matesan MC; Lewis DH; Lopresti BJ; Mathis CA; Okonkwo DO; Mountz JM
    Semin Nucl Med; 2016 Jan; 46(1):57-87. PubMed ID: 26687858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target-specific PET probes for neurodegenerative disorders related to dementia.
    Kadir A; Nordberg A
    J Nucl Med; 2010 Sep; 51(9):1418-30. PubMed ID: 20810758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.
    Silverman DH
    J Nucl Med; 2004 Apr; 45(4):594-607. PubMed ID: 15073255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validating FDG-PET as a biomarker for frontotemporal dementia.
    Foster NL
    Exp Neurol; 2003 Nov; 184 Suppl 1():S2-8. PubMed ID: 14597319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.
    Del Sole A; Malaspina S; Magenta Biasina A
    Funct Neurol; 2016; 31(4):205-215. PubMed ID: 28072381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET radiotracers for molecular imaging in dementia.
    Baskin A; Giannakopoulos P; Ratib O; Seimbille Y; Assal F; Perani D; Garibotto V
    Curr Radiopharm; 2013 Dec; 6(4):215-30. PubMed ID: 24283962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
    de Lartigue J
    Drugs Today (Barc); 2014 Mar; 50(3):219-29. PubMed ID: 24696867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/MR in dementia and other neurodegenerative diseases.
    Barthel H; Schroeter ML; Hoffmann KT; Sabri O
    Semin Nucl Med; 2015 May; 45(3):224-33. PubMed ID: 25841277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive Impairment and Dementias.
    Khosravi M; Newberg A; Alavi A
    Semin Nucl Med; 2018 Nov; 48(6):498-512. PubMed ID: 30322476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain
    Nobili F; Arbizu J; Bouwman F; Drzezga A; Agosta F; Nestor P; Walker Z; Boccardi M;
    Eur J Neurol; 2018 Oct; 25(10):1201-1217. PubMed ID: 29932266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
    Vallabhajosula S
    Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [
    Hellwig S; Frings L; Bormann T; Vach W; Buchert R; Meyer PT
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):312-323. PubMed ID: 30094462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers.
    Bensaïdane MR; Beauregard JM; Poulin S; Buteau FA; Guimond J; Bergeron D; Verret L; Fortin MP; Houde M; Bouchard RW; Soucy JP; Laforce R
    J Alzheimers Dis; 2016 Apr; 52(4):1251-62. PubMed ID: 27104896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET/CT in diagnosis of movement disorders.
    Berti V; Pupi A; Mosconi L
    Ann N Y Acad Sci; 2011 Jun; 1228():93-108. PubMed ID: 21718327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET Agents in Dementia: An Overview.
    van Waarde A; Marcolini S; de Deyn PP; Dierckx RAJO
    Semin Nucl Med; 2021 May; 51(3):196-229. PubMed ID: 33500121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
    Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.